Literature DB >> 7511016

G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.

B J Bolwell1, A Fishleder, S W Andresen, A E Lichtin, A Koo, T Yanssens, R Burwell, P Baucco, R Green.   

Abstract

G-CSF and GM-CSF enhance the rate of neutrophil engraftment in autologous bone marrow transplantation (ABMT) without significantly affecting platelet engraftment. Peripheral blood progenitor cells (PBPC) may enhance rates of engraftment of both neutrophils and platelets. We treated 49 patients undergoing ABMT with a course of G-CSF to obtain PBPC and infused these cells post-transplant with G-CSF in an attempt to determine factors which might correlate with enhanced BM engraftment. Forty-nine patients with Hodgkin's disease, non-Hodgkin's lymphoma or breast cancer undergoing unpurged ABMT were studied. G-CSF priming consisted of an outpatient 8 day course of 5 micrograms/kg/day followed by three leukaphereses (on day 5, 7 and 8) to collect PBPC. Patients then received a chemotherapeutic BMT preparative regimen followed by an infusion of PBPC, autologous BM and the reinstitution of G-CSF (16 micrograms/kg/day). BM engraftment was rapid. The median time to achieve 0.5 x 10(9)/l neutrophils was 10 days compared with a historical BMT control patient population receiving the same preparative regimens of 19 days (p = 0.001). Time to achieve a platelet count of 20 x 10(9)/l was 16 days compared with a historical control of 22 days (p = 0.001). Neutrophil engraftment occurred in all patients by day +14. Marrow engraftment correlated with the total number of CD34+ cells infused as well as the total number of mononuclear cells infused but not the total number of CD34+/CD33- cells infused. The amount of total blood volume pheresed significantly correlated with yield of total mononuclear cells. Prior exposure to radiation therapy negatively correlated with progenitor cell yield.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7511016

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters.

Authors:  L S Hofstra; E G de Vries; C A Uyl-de Groot; E Vellenga
Journal:  Med Oncol       Date:  1996-09       Impact factor: 3.064

2.  Improvement of hematologic recovery after high-dose intensification using peripheral blood progenitor cells (PBPC) mobilized by chemotherapy and GM-CSF.

Authors:  T Lamy; B Drenou; I Grulois; C Leberre; C Dauriac; L Amiot; M Godard; R Fauchet; P Y LePrise
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

3.  Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience.

Authors:  Raul Gabús; Gabriel Borelli; Martín Ferrando; Enrique Bódega; Estela Citrín; Constanza Olivera Jiménez; Ramón Alvarez
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 4.  Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

Authors:  J E Frampton; C R Lee; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

Review 5.  A comparative review of colony-stimulating factors.

Authors:  J Nemunaitis
Journal:  Drugs       Date:  1997-11       Impact factor: 11.431

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.